Cloud-Clone says its ELISA kits have passed 42,000 SCI citations

Cloud-Clone is touting nearly two decades of in-house R&D, more than 10,000 ELISA and CLIA kits, and a global customer base as it positions itself as a benchmark supplier in immunoassays. The company says its products have been cited in more than 42,000 SCI papers by the end of 2025, including work in Nature, Science and Cell.

Why it matters: - Cloud-Clone is trying to compete with established global reagent makers on performance, price and supply-chain control. - The company’s ELISA and CLIA kits are used across medicine, drug discovery, diagnostics, food safety and environmental monitoring. - Its cited publication record is part of the pitch that the company has become a widely used research supplier.

What happened: - Cloud-Clone said it has built a full-chain, in-house manufacturing model over nearly 20 years of R&D. - The company said its products had been cited in more than 42,000 SCI publications by the end of 2025, including more than 350 papers in Nature, Science and Cell. - Cloud-Clone said it was founded in 2009 and now operates three in-house centers for protein production, antibody generation and reagent formulation. - The company said it has developed more than 10,000 ELISA and chemiluminescent immunoassay kits covering more than 10 species and more than 8,000 analytes.

The details: - Cloud-Clone said its workflow covers peptide synthesis, recombinant-protein expression, antibody preparation and kit assembly. - The company said all core raw materials are developed and manufactured internally with full traceability. - Cloud-Clone said its sandwich-format SE and SC series target macromolecular proteins, while its competitive-format CE and CC series target small molecules such as hormones, pharmaceuticals and environmental toxins. - The company said its mini-volume ME series uses 25 μL of sample and is designed for scarce samples from model organisms. - Cloud-Clone said its HE series reaches sensitivity down to 0.3 pg/mL. - The company said its IE series completes workflows in 70 minutes, compared with about 3 hours for traditional formats. - Cloud-Clone said its AE series is designed to quantify autoantibodies including anti-dsDNA and anti-insulin-receptor antibodies. - The company said its PS antibody-pair products and KS raw-material sets support custom assay development. - Cloud-Clone said standard ELISA kits reach sensitivity of 10⁻⁹ mol/L, while its CLIA kits detect down to 10⁻¹⁸ mol/L with linear ranges spanning four to six orders of magnitude. - The company said flagship cytokine and neurotransmitter kits achieve pg-level sensitivity using self-derived high-affinity antibodies and signal-amplification technology. - Cloud-Clone said its quality system includes three-tier QC across raw materials, intermediate batches and finished goods. - The company said every batch is tested for sensitivity, specificity, precision and stability and comes with quality-control reports. - Cloud-Clone said it holds ISO9001:2015 and ISO13485:2016 certifications. - The company said the human IL-6 96-well kit sells for 2,940 currency units. - Cloud-Clone said it offers 24-hour consultation, 72-hour after-sales response and custom-development services. - The company said its products are distributed across dozens of countries and regions, with more than 75% of customers outside domestic markets. - Cloud-Clone said long-term users include the National Institutes of Health, MD Anderson Cancer Center and Cold Spring Harbor Laboratory.

Between the lines: - Cloud-Clone is framing technical self-sufficiency as a competitive advantage against international suppliers that have historically dominated premium ELISA kits. - The company’s emphasis on citations, global institutions and broad target coverage suggests it is using scientific adoption as proof of market credibility. - The pricing claim and service guarantees point to a push for share in cost-sensitive labs that still want high-spec reagents.

What’s next: - Cloud-Clone said it will increase R&D investment to improve antibody screening and signal-amplification workflows. - The company said it plans to add new assay targets and species coverage, including more multiplex and chemiluminescence products. - Cloud-Clone said it will expand custom-development capacity, shorten lead times and build a broader global technical-support network. - The company said it will keep expanding its validated ELISA-kit portfolio for the global research market.

The bottom line: - Cloud-Clone is betting that in-house manufacturing, broad assay coverage and lower prices can turn publication traction into a stronger global position in immunoassay reagents.

More information